On Friday, Truist Securities revised its price target for Walgreens Boots Alliance (NASDAQ:WBA), reducing it significantly from $20.00 to $13.00, while keeping a Hold rating on the stock. This adjustment comes in the wake of Walgreens reporting third-quarter results that fell short of both the firm's and the consensus estimates. The shortfall was attributed to the current tough retail conditions and specific challenges within the pharmacy sector.
In addition to the price target change, Walgreens has announced a strategic review update. This update includes a footprint optimization program that could affect approximately 25% of the company's store network, targeting underperforming locations. While the U.S. Healthcare and International segments reported strong performance for the quarter, overall cash flow did not meet expectations and is considered a crucial factor moving forward.
The firm has revised downwards its adjusted earnings per share (EPS) estimates for the fiscal years 2024 and 2025 and has also introduced its projections for fiscal year 2026. Despite the lower earnings forecasts and the significant reduction in the price target, Truist Securities has decided to maintain a Hold rating on Walgreens shares.
Walgreens' strategic review aims to address the identified challenges through its store optimization program. While the company is taking steps to mitigate the impact of the tough retail and pharmacy headwinds, the firm's updated financial projections reflect a more cautious outlook for the near future.
In other recent news, Walgreens Boots Alliance reported a decrease in its earnings per share (EPS) for the third quarter of fiscal year 2024 to $0.63, falling short of market expectations. This is largely due to challenges faced in the U.S. retail pharmacy sector. Consequently, Walgreens has revised its full-year outlook, anticipating an EPS of $2.80 to $2.95 for fiscal year 2024. In response to these developments, Mizuho Securities adjusted its outlook on Walgreens, reducing the price target to $15.00 from the previous $19.00 while maintaining a Neutral rating on the stock.
The company has initiated a strategic review to address these issues, including plans to refine its business model and invest in sectors like Boots UK and VillageMD. Despite the difficulties, there are positive signs from Walgreens' International and U.S. Healthcare segments, which are expected to mitigate some pressures. The company is also considering closing up to 25% of its stores based on cash flow analysis. These recent changes reflect Walgreens' proactive approach to industry challenges and its commitment to future success.
InvestingPro Insights
In light of Truist Securities' recent price target adjustment for Walgreens Boots Alliance (NASDAQ:WBA), a look at the latest InvestingPro data reveals additional context. The company's market capitalization stands at $10.52 billion, reflecting the scale of the business amidst current market conditions. Despite a challenging quarter, Walgreens has demonstrated revenue growth, with the last twelve months as of Q2 2024 showing an 8.48% increase to $144.6 billion. This growth is complemented by a gross profit of $26.88 billion, indicating a gross profit margin of 18.59%. However, the company's negative P/E ratios, both current and adjusted for the last twelve months (-2.32 and -13.16 respectively), suggest investor concerns about profitability.
InvestingPro Tips highlight the substantial dividend yield of 8.2%, which could be attractive to income-focused investors, especially in contrast to the negative price returns over various time frames, including a 55.21% drop over the past year. The InvestingPro platform offers even more insights, with additional tips that could guide investors through Walgreens' current situation. For those considering a deeper dive, use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.